EFFECTS OF TENOFOVIR ALAFENAMIDE FUMARATE VERSUS TENOFOVIR DISOPROXIL FUMARATE ON SERUM LIPID PROFILES IN PATIENTS WITH CHRONIC HEPATITIS B

被引：0
|
作者：
Cao, Fei [1 ]
Fan, Tao [1 ]
Jiang, Xue [2 ]
Wang, Jian [3 ]
Xiong, Ye [1 ,3 ]
Zhang, Shaoqiu
Zhang, Zhiyi [1 ]
Liu, Xingxiang [2 ]
Zhu, Chuanwu [4 ]
Li, Jie [3 ]
Huang, Rui [3 ]
Wu, Chao [3 ]
机构：
[1] Nanjing Univ, Clin Coll, Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[2] Huaian 4 Peoples Hosp, Huaian, Peoples R China
[3] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Sch Med, Nanjing, Peoples R China
[4] Soochow Univ, Affiliated Infect Dis Hosp, Suzhou, Peoples R China
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
412
引用
收藏
页码：S298 / S298
页数：1
相关论文
共 50 条
  • [41] REAL WORLD COMPARISON OF RENAL SAFETY IN PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE VS TENOFOVIR ALAFENAMIDE FOR CHRONIC HEPATITIS B
    Zhang, Xueyun
    Hu, Qiankun
    Liu, Xiaoqin
    Huang, Yuxian
    HEPATOLOGY, 2021, 74 : 490A - 491A
  • [42] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, Andrew
    Hughes, Sophie L.
    Gotham, Dzintars
    Pozniak, Anton L.
    JOURNAL OF VIRUS ERADICATION, 2018, 4 (02) : 72 - 79
  • [43] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
    De Clercq, Erik
    BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
  • [44] Evaluation of Tenofovir Disoproxil Fumarate Treatment in Patients with Chronic Hepatitis B
    Konya, Petek
    Demirturk, Nese
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2022, 4 (01): : 47 - 54
  • [45] Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
    Aloy, Blandine
    Tazi, Imane
    Bagnis, Corinne Isnard
    Gauthier, Marion
    Janus, Nicolas
    Launay-Vacher, Vincent
    Deray, Gilbert
    Tourret, Jerome
    AIDS REVIEWS, 2016, 18 (04) : 184 - 192
  • [46] Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Treatment of Patients with Hepatitis B Following Liver Transplantation
    Cheng, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 1037 - 1037
  • [47] Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply
    Hong, Hyeyeon
    Choi, Jonggi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (02)
  • [48] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE: ASSESSING THE CHANGE IN RENAL FUNCTION IN HEPATITIS B PATIENTS
    Lee, Minna
    Lee, Susan M. K.
    Bernstein, David Eric
    HEPATOLOGY, 2019, 70 : 316A - 316A
  • [49] COST CONSEQUENCE ANALYSIS OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE FOR THE MANAGEMENT OF CHRONIC HEPATITIS B: AN INDIAN SCENARIO
    Hadigal, Sanjay
    Naidu, Ravishankar
    HEPATOLOGY, 2020, 72 : 480A - 481A
  • [50] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Wai-Kay Seto
    Man-Fung Yuen
    James Fung
    Ching-Lung Lai
    Hepatology International, 2013, 7 : 327 - 334
12345